Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Norgaard, Mette L ^a   Andersson, Charlotte ^a   Hansen, Peter R ^a   Andersen, Søren S ^a   Vaag, Allan ^b   Schramm, Tina K ^c   Folke, Fredrik ^a   Køber, Lars ^c,d   Torp Pedersen, Christian ^a,d   Gislason, Gunnar H ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; METFORMIN PLUS REPAGLINIDE; REPAGLINIDE; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; DENMARK; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHARMACY; POPULATION; PRESCRIPTION; BLOOD; CLINICAL PRACTICE; DRUG EFFECT; DRUG UTILIZATION; GLUCOSE BLOOD LEVEL; HEALTH CARE SURVEY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; REGISTER; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DENMARK; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; FEMALE; HEALTH CARE SURVEYS; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 78651506510     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-5     Document Type: Article

References (31)

1. Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J 2003, 24(9):838-844. 10.1016/S0195-668X(02)00828-X, 12727151.
2. Egstrup M, Henriksen FL, Hofsten DE, Jensen BK, Hangaard J, Egstrup K. Prevalence of glucometabolic abnormalities in connection with myocardial infarction in a Danish coronary care unit. Ugeskr Laeger 2008, 170(11):942-946.
3. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, Standl E, Soler-Soler J, Ohrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004, 25(21):1880-1890. 10.1016/j.ehj.2004.07.027, 15522466.
4. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004, 25(22):1990-1997. 10.1016/j.ehj.2004.09.021, 15541834.
5. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. , http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-diabetes-FT.pdf
6. Diabetes og hjertesygdom. , http://cardio.synkron.com/graphics/toimport/cardio/user_graphics/Dokumenter/rapporter_pdf/dm08.pdf
7. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999, 46(3):263-268.
8. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003, 56(2):124-130. 10.1016/S0895-4356(02)00591-7, 12654406.
9. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol 2001, 37(4):992-997. 10.1016/S0735-1097(01)01109-3, 11263626.
10. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. , http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf
11. Association AD. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010, 33(Supplement 1):S62-S69. 10.2337/dc10-S062, 2797383, 20042775.
12. Seibaek M, Sloth C, Vallebo L, Hansen T, Urhammer SA, Burchardt H, Torp-Pedersen C, Pedersen O, Hildebrandt P. Glucose tolerance status and severity of coronary artery disease in men referred to coronary arteriography. Am Heart J 1997, 133(6):622-629. 10.1016/S0002-8703(97)70163-7, 9200389.
13. Lexis CP, Rahel BM, Meeder JG, Zijlstra F, van der Horst IC. The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus. Cardiovasc Diabetol 2009, 8:41. 10.1186/1475-2840-8-41, 2727510, 19635170.
14. Hofsten DE, Logstrup BB, Moller JE, Pellikka PA, Egstrup K. Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis. JACC Cardiovasc Imaging 2009, 2(5):592-599. 10.1016/j.jcmg.2009.03.007, 19442946.
15. Kumler T, Gislason GH, Kober L, Torp-Pedersen C. Diabetes is an independent predictor of survival 17 years after myocardial infarction: follow-up of the TRACE registry. Cardiovasc Diabetol 2010, 9:22. 10.1186/1475-2840-9-22, 2893120, 20525192.
16. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(1):193-203. 10.2337/dc08-9025, 2606813, 18945920.
17. Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 2008, 51(12):2187-2196. 10.1007/s00125-008-1156-z, 18815769.
18. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993, 329(5):304-309. 10.1056/NEJM199307293290502, 8147960.
19. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329(14):977-986. 10.1056/NEJM199309303291401, 8366922.
20. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28(2):103-117. 10.1016/0168-8227(95)01064-K, 7587918.
21. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854-865. 10.1016/S0140-6736(98)07037-8, 9742977.
22. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853. 10.1016/S0140-6736(98)07019-6, 9742976.
23. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139. 10.1056/NEJMoa0808431, 19092145.
24. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572. 10.1056/NEJMoa0802987, 18539916.
25. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559. 10.1056/NEJMoa0802743, 18539917.
26. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32(1):187-192. 10.2337/dc08-9026, 2606812, 19092168.
27. Fu AZ, Qiu Y, Radican L, Yin DD, Mavros P. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study. Cardiovasc Diabetol 2010, 9:15. 10.1186/1475-2840-9-15, 2876102, 20409333.
28. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997, 314(7093):1512-1515. 2126756, 9169397.
29. Jorgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, Vaag A, Abildstrom SZ, Torp-Pedersen C, Hansen PR. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study. Cardiovasc Diabetol 2010, 9:54. 10.1186/1475-2840-9-54, 2946277, 20843380.
30. Jorgensen CH, Gislason GH, Bretler D, Sorensen R, Norgaard ML, Hansen ML, Schramm TK, Abildstrom SZ, Torp-Pedersen C, Hansen PR. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction - A nationwide study. Int J Cardiol 2010,
31. Abildstrom SZ, Rasmussen S, Madsen M. Changes in hospitalization rate and mortality after acute myocardial infarction in Denmark after diagnostic criteria and methods changed. Eur Heart J 2005, 26(10):990-995. 10.1093/eurheartj/ehi039, 15618048.